Cangrelor Use in Routine Practice: A Two-Center Experience

Cangrelor is the first and only intravenous P2Y(12)-inhibitor and is indicated when (timely) administration of an oral P2Y(12) inhibitor is not feasible in patients undergoing percutaneous coronary intervention (PCI). Our study evaluated the first years of cangrelor use in two Dutch tertiary care ce...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Sangen, Niels M. R., Cheung, Ho Yee, Verouden, Niels J. W., Appelman, Yolande, Beijk, Marcel A. M., Claessen, Bimmer E. P. M., Delewi, Ronak, Knaapen, Paul, Lemkes, Jorrit S., Nap, Alexander, Vis, M. Marije, Kikkert, Wouter J., Henriques, José P. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269409/
https://www.ncbi.nlm.nih.gov/pubmed/34206905
http://dx.doi.org/10.3390/jcm10132829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269409/
https://www.ncbi.nlm.nih.gov/pubmed/34206905
http://dx.doi.org/10.3390/jcm10132829

Ejemplares similares